$REGN REGENERON PHARMACEUTICALS, INC. Insider Trading Week 15/2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in REGENERON PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in REGENERON PHARMACEUTICALS, INC. in week 15/2020.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 5,000 | 296,000 | 34,933 | |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 525.30 | 6 | 3,152 | 14,438 | 14.4 K to 14.4 K (-0.04 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 524.99 | 106 | 55,649 | 14,444 | 14.6 K to 14.4 K (-0.73 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 521.05 | 113 | 58,879 | 14,550 | 14.7 K to 14.6 K (-0.77 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 520.45 | 220 | 114,499 | 14,663 | 14.9 K to 14.7 K (-1.48 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 519.43 | 286 | 148,557 | 14,883 | 15.2 K to 14.9 K (-1.89 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 518.25 | 499 | 258,607 | 15,169 | 15.7 K to 15.2 K (-3.18 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 517.40 | 266 | 137,628 | 15,668 | 15.9 K to 15.7 K (-1.67 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 516.81 | 260 | 134,371 | 15,934 | 16.2 K to 15.9 K (-1.61 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 515.70 | 414 | 213,500 | 16,194 | 16.6 K to 16.2 K (-2.49 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 514.63 | 92 | 47,346 | 16,608 | 16.7 K to 16.6 K (-0.55 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 521.45 | 2,738 | 1,427,730 | 16,700 | 19.4 K to 16.7 K (-14.09 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 5,000 | 296,000 | 19,438 | 14.4 K to 19.4 K (+34.63 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,500 | 954,450 | 35,500 | |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 525.30 | 2 | 1,051 | 24,373 | 24.4 K to 24.4 K (-0.01 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 520.36 | 130 | 67,647 | 24,375 | 24.5 K to 24.4 K (-0.53 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 519.58 | 76 | 39,488 | 24,505 | 24.6 K to 24.5 K (-0.31 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 518.31 | 287 | 148,755 | 24,581 | 24.9 K to 24.6 K (-1.15 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 517.84 | 304 | 157,423 | 24,868 | 25.2 K to 24.9 K (-1.21 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 516.89 | 54 | 27,912 | 25,172 | 25.2 K to 25.2 K (-0.21 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 521.45 | 2,647 | 1,380,278 | 25,226 | 27.9 K to 25.2 K (-9.50 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,500 | 954,450 | 27,873 | 24.4 K to 27.9 K (+14.36 %) |
| Apr 15 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Option Exercise | M | 52.03 | 13,079 | 680,500 | 25,000 | |
| Apr 15 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 524.26 | 357 | 187,161 | 11,380 | 11.7 K to 11.4 K (-3.04 %) |
| Apr 15 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 522.37 | 758 | 395,956 | 11,737 | 12.5 K to 11.7 K (-6.07 %) |
| Apr 15 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 521.32 | 1,595 | 831,505 | 12,495 | 14.1 K to 12.5 K (-11.32 %) |
| Apr 15 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 520.43 | 2,096 | 1,090,821 | 14,090 | 16.2 K to 14.1 K (-12.95 %) |
| Apr 15 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 519.85 | 422 | 219,377 | 16,186 | 16.6 K to 16.2 K (-2.54 %) |
| Apr 15 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 518.54 | 267 | 138,450 | 16,608 | 16.9 K to 16.6 K (-1.58 %) |
| Apr 15 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 517.99 | 2 | 1,036 | 16,875 | 16.9 K to 16.9 K (-0.01 %) |
| Apr 15 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Payment of Exercise | F | 511.56 | 7,582 | 3,878,648 | 16,877 | 24.5 K to 16.9 K (-31.00 %) |
| Apr 15 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Buy | M | 52.03 | 13,079 | 680,500 | 24,459 | 11.4 K to 24.5 K (+114.93 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,500 | 954,450 | 39,000 | |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 517.71 | 46 | 23,815 | 24,373 | 24.4 K to 24.4 K (-0.19 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 512.58 | 31 | 15,890 | 24,419 | 24.5 K to 24.4 K (-0.13 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 511.59 | 156 | 79,808 | 24,450 | 24.6 K to 24.5 K (-0.63 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 510.43 | 143 | 72,991 | 24,606 | 24.7 K to 24.6 K (-0.58 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 509.45 | 170 | 86,607 | 24,749 | 24.9 K to 24.7 K (-0.68 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 508.54 | 115 | 58,482 | 24,919 | 25 K to 24.9 K (-0.46 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 507.45 | 30 | 15,224 | 25,034 | 25.1 K to 25 K (-0.12 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 506.24 | 38 | 19,237 | 25,064 | 25.1 K to 25.1 K (-0.15 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 505.60 | 99 | 50,054 | 25,102 | 25.2 K to 25.1 K (-0.39 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 508.25 | 2,672 | 1,358,044 | 25,201 | 27.9 K to 25.2 K (-9.59 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,500 | 954,450 | 27,873 | 24.4 K to 27.9 K (+14.36 %) |